Loading…
Halozyme Therapeutics, Inc. is projected to rise to $78.42 by 2027, a +14% move from its current price of $68.65. HALO is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $67.54 | $68.65 | $69.78 | 0.00% |
| May 30 | $67.09 | $68.66 | $70.26 | +0.01% |
| May 31 | $66.75 | $68.66 | $70.62 | +0.01% |
| Jun 1 | $66.46 | $68.66 | $70.93 | +0.02% |
| Jun 2 | $66.21 | $68.66 | $71.21 | +0.02% |
| Jun 3 | $65.98 | $68.67 | $71.46 | +0.02% |
| Jun 4 | $65.77 | $68.67 | $71.69 | +0.03% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $65.77 | $68.67 | $71.69 | +0.03% |
| Week 2 | $64.62 | $68.69 | $73.00 | +0.05% |
| Week 3 | $63.76 | $68.70 | $74.03 | +0.08% |
| Week 4 | $63.05 | $68.72 | $74.91 | +0.11% |
| Week 5 | $62.43 | $68.74 | $75.70 | +0.13% |
| Week 6 | $61.87 | $68.76 | $76.41 | +0.16% |
| Week 7 | $61.36 | $68.78 | $77.08 | +0.18% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Halozyme Therapeutics, Inc. is a healthcare company that researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally.
Its products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy. The company also provides Herceptin (trastuzumab) under the brand name Herceptin Hylecta; and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; Tecentriq SC for IV infusion; Ocrevus SC for multiple sclerosis; HYQVIA to treat primary immunodeficiency disorders; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat metastatic or unresectable melanoma; teriparatide injections; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy.
The company has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc.; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; Acumen Pharmaceuticals, Inc.; Merus N.V.; and Skye Bioscience, Inc.
The company was founded in 1998 and is headquartered in San Diego, California.
Halozyme Therapeutics, Inc. is a healthcare stock trading at $68.32, with a market capitalization of $8.1B and a rank of 1038 by market cap.
The 3-4 year price outlook shows a rising trajectory across the forecast, starting with a 2026 average price of $68.32 and moving higher in subsequent years.
Forecasts show a bullish path into the late 2020s and beyond, with per-year averages advancing from $68.32 in 2026 to $78.19 (2027), $92.09 (2028), and $106.87 (2029), then continuing to $124.91 (2030), $286.19 (2040), and $630.34 (2050).
Max and min forecast values imply substantial upside potential, with 2030 max of $170.66, 2040 max of $437.03, and 2050 max of $1,031.50. 2026 shows a flat start with min $61.63 and max $90.76. The forecast also lists rising ROIs through the horizon, from 0 in 2026 to 82.8 in 2030 and 822.6 in 2050.
A major floor 13.1% below — a decisive break under it would weaken the trend.
The nearest floor, 8.1% below — buyers have tended to step in here.
The nearest ceiling, 3.3% above — a clean break opens room to run.
A major ceiling 18.3% above — clearing it would confirm fresh momentum.
Key HALO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of HALO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $68.64 | Buy | $68.56 | Buy |
| MA 10 | $68.57 | Buy | $68.26 | Buy |
| MA 20 | $66.99 | Buy | $67.62 | Buy |
| MA 50 | $65.94 | Buy | $67.25 | Buy |
| MA 100 | $69.02 | Sell | $67.62 | Buy |
| MA 200 | $69.18 | Sell | $66.72 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 55.35 | Neutral |
| Stoch RSI (14) | 55.30 | Neutral |
| CCI (20) | 56.00 | Neutral |
| Williams %R (14) | -33.48 | Info |
| MACD (12,26,9) | 0.14 | Buy |
| ROC (12) | 7.06 | Buy |
| Bollinger %B (20,2) | 0.68 | Neutral |
| Stochastic %K (14) | 66.52 | Neutral |
| TRIX (15) | 0.13 | Buy |
| Awesome (5,34) | 1.59 | Buy |
| Ultimate (7,14,28) | 67.20 | Neutral |
| Momentum (10) | -2.28 | Sell |
| Aroon Osc (25) | 36.00 | Buy |
| Hull MA (9) | 68.67 | Sell |
| ADX (14) | 12.59 | Neutral |
| ATR (14) | 0.93 | Info |
The 30-day technical picture is bullish.
The RSI(14) is 50, and the 50-day simple moving average is $65.75 while the 200-day simple moving average is $69.12.
Support is at $63.06 and resistance at $70.93, with a 30-day price range from $60.96 to $76.57. Annualized volatility is 30%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $61.63 | $68.65 | $90.97 | 0% | Neutral | |
| $64.06 | $78.42 | $100.47 | +14% | Neutral | |
| $73.68 | $91.84 | $120.75 | +34% | Bullish | |
| $84.48 | $106.89 | $143.46 | +56% | Bullish | |
| $97.40 | $124.88 | $170.57 | +82% | Bullish | |
| $112.14 | $145.53 | $201.87 | +112% | Bullish | |
| $116.00 | $152.22 | $214.12 | +122% | Bullish | |
| $118.98 | $157.75 | $224.75 | +130% | Bullish | |
| $128.47 | $172.03 | $247.99 | +151% | Bullish | |
| $146.20 | $197.61 | $288.01 | +188% | Bullish | |
| $201.27 | $283.68 | $433.15 | +313% | Bullish | |
| $415.15 | $627.47 | $1,026.71 | +814% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $61.63 | $68.65 | $80.30 | +0.00% |
| June 2026 | $58.31 | $68.02 | $80.89 | -0.91% |
| July 2026 | $58.71 | $68.89 | $82.69 | +1.27% |
| August 2026 | $59.94 | $70.64 | $85.42 | +2.55% |
| September 2026 | $59.35 | $70.21 | $85.40 | -0.61% |
| October 2026 | $58.71 | $69.69 | $85.22 | -0.75% |
| November 2026 | $60.28 | $71.77 | $88.18 | +2.98% |
| December 2026 | $61.74 | $73.71 | $90.97 | +2.71% |
Click any year to see its month-by-month HALO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, HALO is projected to trade between $61.63 and $90.97, averaging $68.65 — a potential gain of 0% from today's $68.65. A consolidation phase looks the most probable path here.
Halozyme Therapeutics, Inc.'s 2027 outlook centres on $78.42, within a $64.06 to $100.47 range. That is up +14% on the projected 2026 average. That marks a +14% change versus current levels. Price action looks broadly range-bound.
By 2028, HALO could reach as high as $120.75, with a base case around $91.84 and support toward $73.68 — roughly +34% from $68.65. Buyers look set to stay in control over this stretch.
Expect HALO to range from $84.48 to $143.46 through 2029. The $106.89 average target implies a +56% move from current prices. That is up +16% on the projected 2028 average. Momentum favours further upside here.
The HALO price prediction for 2030 points to an average of $124.88 (low $97.40, high $170.57) — a potential gain of +82% on today's $68.65. Buyers look set to stay in control over this stretch.
In 2031, HALO is projected to trade between $112.14 and $201.87, averaging $145.53 — a potential gain of +112% from today's $68.65. That is up +17% on the projected 2030 average. Momentum favours further upside here.
Halozyme Therapeutics, Inc.'s 2032 outlook centres on $152.22, within a $116.00 to $214.12 range. That is up +5% on the projected 2031 average. That marks a +122% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, HALO could reach as high as $224.75, with a base case around $157.75 and support toward $118.98 — roughly +130% from $68.65. Momentum favours further upside here.
Expect HALO to range from $128.47 to $247.99 through 2034. The $172.03 average target implies a +151% move from current prices. That is up +9% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The HALO price prediction for 2035 points to an average of $197.61 (low $146.20, high $288.01) — a potential gain of +188% on today's $68.65. Momentum favours further upside here.
In 2040, HALO is projected to trade between $201.27 and $433.15, averaging $283.68 — a potential gain of +313% from today's $68.65. That is up +44% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Halozyme Therapeutics, Inc.'s 2050 outlook centres on $627.47, within a $415.15 to $1,026.71 range. That is up +121% on the projected 2040 average. That marks a +814% change versus current levels. Momentum favours further upside here.
Investing $1,000 in HALO today (≈ 14.566642 HALO) could be worth
$9,140.12
+$8,140.12 (+814%) by 2050 · US Dollar
Based on the average projected HALO price of $627.47 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in HALOwould be worth at today's price.
$1,000 invested in HALO on May 27, 2025 (≈ 18.375598 HALO) would be worth
$1,261.48
+$261.48 (+26.1%) today · 1.26× · US Dollar
Based on a HALO entry price of $54.42 vs. today's $68.65.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $68.98 | $995.22 | -0.5% |
| 1 month ago | $64.49 | $1,064.51 | +6.5% |
| 3 months ago | $69.22 | $991.77 | -0.8% |
| 6 months ago | $71.4 | $961.48 | -3.9% |
| 1 year ago | $54.42 | $1,261.48 | +26.1% |
| All time (5.0y) ago | $41.38 | $1,659.01 | +65.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our HALO forecast.
Our base-case forecast reaches $140.00 around 2031.
Implied market cap at $140.00: $16.61B
The multi-year forecast shows a bullish trajectory across the horizon, with early-year momentum giving way to stronger gains later. The sequence of annual averages suggests steady appreciation, with 2026 at $68.32, 2027 at $78.19, 2028 at $92.09, and 2029 at $106.87, accompanied by rising ROIs (0, 14.4, 34.8, 56.4).
In 2030, the average price is forecast at $124.91, with a min of $97.41 and a max of $170.66, and an ROI of 82.8; sentiment is BULLISH.
In 2040, the average price is forecast at $286.19, with a min of $203.02 and a max of $437.03, and an ROI of 318.9; sentiment is BULLISH.
In 2050, the average price is forecast at $630.34, with a min of $417.02 and a max of $1,031.50, and an ROI of 822.6; sentiment is BULLISH.
These are estimates, not guarantees, and actual results may differ. The forecasts imply substantial upside potential but also carry inherent uncertainty.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $124.91, with a min of $97.41 and a max of $170.66, and an ROI of 82.8; sentiment is BULLISH.
The forecast indicates a bullish path through 2027–2050, with rising average prices and positive ROIs (e.g., 2027 avg 78.19; ROI 14.4; 2030 avg 124.91; ROI 82.8; 2050 avg 630.34; ROI 822.6). These are estimates, not guarantees, and actual results may vary.
Yes. The 2030 max forecast is $170.66, indicating the stock could reach that level according to the forecast.
The current price is $68.32 and the market capitalization is $8.1B; the stock ranks 1038 by market cap.
The 30-day range is from $60.96 to $76.57, and the annualized volatility is 30%.
Halozyme Therapeutics, Inc. Community Discussion
0Share your Halozyme Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.